Articles tagged with Drug Combinations
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
The PATINA trial demonstrates a significant progression-free survival benefit with palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The study showed a median progression-free survival of 44.3 months, compared to 29.1 months in the control arm.
A recent study found that high doses of rifampicin do not improve survival rates among adults with tuberculous meningitis. The researchers are now exploring alternative treatments targeting inflammation in the brain membranes and investigating TNF inhibitors as potential therapies.
Acute sepsis alters fluid kinetics and creates a 'third space' resistant to adrenergic modulation, leading to maldistribution of crystalloid fluid. Vasoactive drugs have limited effect on fluid distribution in septic sheep compared to healthy animals.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
The azacitidine-venetoclax combination significantly improves event-free survival and overall response rates compared to intensive chemotherapy. Patients in the aza-ven arm also experience lower symptom burdens, reduced depression, and improved quality of life.
A new trial comparing continuous and fixed-duration treatments for CLL found equivalent outcomes in terms of risk of death or disease progression. Fixed-duration treatment was non-inferior to continuous treatment, suggesting clinically equal efficacy.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
A combination treatment of ibrutinib and ianalumab allowed some patients with CLL to discontinue daily therapy and potentially improve their quality of life. The study found that 43.6% of patients had undetectable measurable residual disease, and 17 patients were able to stop ibrutinib and remain off therapy for 12 to 24 months.
A large global study of 23,000 people found that proton pump inhibitors (PPIs) used for indigestion and heartburn were associated with poorer overall survival and a higher risk of severe side effects in patients with breast cancer. Statins and metformin showed no significant impact on either survival or adverse events.
Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.
Scientists at the University of Cambridge created a smarter way to activate the immune system against cancer by harnessing the STING pathway. The new two-part prodrug system triggers the immune response only in tumour tissues, reducing harm to healthy cells.
A study of 2,201 patients after heart bypass surgery showed that dual antiplatelet therapy with ticagrelor and aspirin did not reduce cardiovascular risks but increased the risk of excessive bleeding. The results contradict current guidelines recommending dual therapy for these patients.
Researchers validated panels of antibodies targeting clinically relevant nucleic acid modifications to visualize antisense oligonucleotides in both in vitro and in vivo studies. The tools enable detection of modified nucleic acids irrespective of sequence, facilitating multiple clinical and pre-clinical workflows.
A new study from the University of Bath found that inappropriate polypharmacy is a major driver of emergency hospital admissions among adults aged 65 and over. The researchers developed a digital tool to proactively identify older adults at risk of medication-related harm, which could reduce preventable emergency hospitalisations.
Researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine aim to reduce falls and adverse drug events among older adults by using personalized approach tailored to individual genetic profiles.
A study found that prescribing guideline-directed medical treatment to patients 90 years and older following their first heart attack can improve survival rates. The greatest benefit was observed in those who received all four recommended therapies, including beta-blockers and renin-angiotensin-aldosterone system inhibitors.
Researchers developed a treatment strategy to address fentanyl-xylazine overdoses, combining naloxone with atipamezole to improve recovery outcomes in animal models. The co-administration of naloxone and atipamezole restored consciousness and physiological parameters in rats exposed to fentanyl and xylazine.
Researchers found that denosumab increases tumour-infiltrating immune cells in early-stage breast cancer patients, particularly in type B luminal tumours. This increase is associated with a potential boost to the anti-tumor immune response and offers a valuable avenue for clinical interest.
Researchers at the University of Chicago Medicine discovered a new phenomenon where high doses of radiation cause growth in existing metastatic tumors. The 'badscopal effect' is attributed to increased production of amphiregulin, which weakens the immune system and makes cancer cells more resistant.
Dr. Rakesh Jain has received the AACR Lifetime Achievement Award for his groundbreaking theory of vascular normalization, which challenged conventional wisdom in antiangiogenic therapies. His work has directly contributed to FDA approval of several drug combinations, enhancing outcomes for patients with various cancers.
A study published in Food Chemistry: Molecular Sciences found that cinnamaldehyde in cinnamon activates receptors controlling medication clearance, raising concerns about potential interactions. Researchers recommend consulting a doctor before using cinnamon as a dietary supplement to avoid rapid clearance of prescription medicines.
A new study estimates that 2.7% of NYC electronic dance music-nightclub attending adults used Tusi in the past year, with risks of adverse or unexpected effects due to its often adulterated nature. The use of Tusi has been reported in Latin America and Europe since the past decade.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
Researchers have identified a combination of drugs that prevents enteroviruses from replicating, which could lead to an effective treatment for global health problem. The combination includes pleconaril, AG7404, and mindeudesivir, which shows great potential for finding broad-spectrum treatment methods against enteroviruses.
A new clinical trial at the University of Miami Miller School of Medicine is testing a novel combination of immunotherapy drugs and an oncolytic virus to treat high-grade neuroendocrine cancer. The trial aims to find safe combination doses and compare effectiveness with standard-of-care treatment.
Researchers found that combining imipridones with radiation therapy and temozolomide slowed glioblastoma growth and prolonged survival in mice. The treatment also boosted immune responses and suppressed MGMT protein expression, making it more effective.
Researchers created a thromboinflammation-on-a-chip model that can sustain blood clots for several months and track treatment options. This model reveals critical information on clot resolution and suggests new drug combinations to protect endothelial function in patients with sickle cell disease.
A natural citrus oil, when combined with a lipid formulation, may effectively relieve dry mouth in cancer patients. The new formula has demonstrated improved solubility and bioavailability compared to pure limonene.
A large study suggests that patients at high risk of heart attacks and strokes should be treated immediately with a combination of a statin and ezetimibe, rather than statins alone. This combination therapy significantly reduces the risk of death from any cause and major adverse cardiovascular events.
Researchers at Institute for Systems Biology (ISB) have discovered a non-genetic adaptation mechanism that allows melanoma cells to evade BRAF inhibitors within hours. By blocking this early response with a combination therapy approach, the study aims to improve treatment outcomes and prolong the effectiveness of existing treatments.
Researchers found that curcumin enhances the effectiveness of bedaquiline in combating M. abscessus infections, with the combination showing synergistic enhancement of antibacterial activity. The study suggests potential new treatment pathways for resistant infections, particularly in immunocompromised populations.
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
Researchers at University of North Carolina Health Care found that combination immunotherapy before surgery increased survival rates in people with head and neck squamous cell carcinomas. The treatment regimen doubled or tripled the response rate versus single immunotherapy, leading to a survival benefit for up to a third of patients.
Researchers have made a breakthrough in treating thymic carcinoma by combining immune checkpoint inhibitors with platinum-based chemotherapy. The MARBLE study found that atezolizumab combined with carboplatin and paclitaxel achieved an objective response rate of 56% and median progression-free survival of 9.6 months.
A new study by researchers at UCSF has found that long-acting injectable treatments can be transformative for patients who struggle to take daily HIV pills, resulting in undetectable viral loads and improved health outcomes. The treatment approach could help stop the spread of HIV by keeping more patients from being infectious.
Researchers at VCU Massey Comprehensive Cancer Center have identified an innovative combination treatment strategy that collaborates to kill AML cells. The new approach targets the SRC gene and MCL-1 protein, leading to increased cell death in leukemia cells. This discovery offers a promising new direction for leukemia treatment.
The ESMO Targeted Anticancer Therapies Congress 2025 features state-of-the-art presentations on new targets, tumour-agnostic drug development, and the role of artificial intelligence in cancer treatment. The congress also highlights recent study results and their potential impact on precision medicine.
A study analyzing millions of U.S. prescriptions over 10 years found that co-prescribed stimulants and opioids are associated with escalating opioid intake. Patients taking both stimulants and opioids had a higher average monthly intake of morphine milligram equivalents (MME) compared to those taking only opioids.
Researchers at Mount Sinai developed iDOMO, a computational tool that predicts effective drug pairings using gene expression data. The study successfully identified a promising combination for triple-negative breast cancer, validating its prediction.
Researchers found that radiation combined with immune checkpoint inhibitors durvalumab and tremelimumab resulted in durable responses allowing for bladder preservation in localized MIBC patients. The study showed a high efficacy rate of 93% complete response rate, with 84% overall survival rate after two years.
Researchers at Dana-Farber Cancer Institute present studies on novel treatments for prostate, kidney, and bladder cancers. The team introduces a novel HIF-2α inhibitor called casdatifan, which shows promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma.
A new tool named retriever extracts disease-specific drug response signatures to predict cancer treatment combinations, improving personalized treatment strategies. The tool refines predictions using single-cell RNA sequencing data and demonstrates its potential in identifying effective treatments for triple-negative breast cancer.
Researchers identified a potential new treatment for aggressive sarcoma arising in nerves, using a pre-clinical platform that combines inhibitors targeting specific mutations. The triple combination of MEKi-BETi-CDKi showed promising results in shrinking tumors and even eliminating some cases, offering hope for improved treatment options.
A new combination therapy combining systemic interferon-I with local imiquimod application showed promising results in treating melanoma and breast cancer. The therapy activated the adaptive immune system to fight distant metastases, reducing tumor relapses and increasing sensitivity to checkpoint inhibitors.
Researchers analyzed 101 Chinese AML samples and identified three subtypes with different molecular characteristics and clinical outcomes. The study also found potential drug combinations that could improve treatment efficacy for subtype S-II&III patients who benefited from allogenic haematopoietic stem cell transplantation.
A phase 2 study found that the combination of belzutifan and cabozantinib produced a confirmed objective response rate of 70% among patients with advanced clear-cell renal cell carcinoma. The treatment was well-tolerated, with manageable serious adverse events.
Researchers discovered that the protein PIN1 drives bladder cancer by triggering cholesterol synthesis, which fuels out-of-control cell growth. A combination of statins and a PIN1 inhibitor effectively blocks tumor growth in mice, offering a promising therapeutic approach for this deadly disease.
A novel drug combination of albendazole and ivermectin demonstrates superior efficacy in treating Trichuris trichiura and other soil-transmitted helminths. The treatment has shown safety in a phase II-III trial, potentially aiding endemic countries in meeting the WHO's Roadmap for Neglected Tropical Diseases.
A team of researchers at USC will receive funding to test a novel approach to slowing age-related cognitive decline, targeting the brain's lymphatic system. The grant aims to delay the onset of Alzheimer's and Parkinson's disease by clearing waste buildup.
Adding camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response in patients with early or locally advanced triple-negative breast cancer. The treatment showed substantial benefits, leading researchers to explore its potential as a neoadjuvant strategy.
Researchers found that a new chemotherapy regimen, eBEACOPDac, resulted in fewer and less severe side effects compared to the existing regimen, eBEACOPP. Patients treated with eBEACOPDac experienced improved fertility recovery and reduced hospital time, making it a potential game-changer for treating Hodgkin lymphoma.
A Virginia Tech researcher has received a collaborative grant to improve cancer therapies by developing 3D liver organoids and employing cutting-edge microscopy technology. The project aims to identify the most effective treatments for cancer, enabling better-targeted treatments.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
A clinical trial found that combining two commonly recommended medications into a single pill lowered blood pressure and was safe among Indian adults. The study's results have significant meaning for South Asian adults, including those living in the US.
A $3.96 million grant will support the development of a monitoring device and data-processing algorithm to guide combination therapy design against multidrug-resistant bacteria. The goal is to overcome bacterial defenses and combat the emergence of resistance.
A new combination of immunotherapy and epigenetic drug may transform resistant pancreatic tumors into susceptible ones, according to a study by Johns Hopkins Medicine researchers. The treatment showed promise in a subset of patients, with tumor shrinkage and durable responses observed over several months.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
A new research project will test a combination of two targeted therapies, teclistamab and daratumumab, to treat AL amyloidosis, a rare disease affecting approximately 4,500 people annually in the U.S. The study aims to leverage previous findings from multiple myeloma to expand understanding of this treatment option.
The ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present several abstracts at the 66th American Society of Hematology Meeting & Exposition. Promising results from a phase 2 study in acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial show improved outcomes for patients with B-cell acute lymphobla...